iShares Biotechnology ETF
858 hedge funds and large institutions have $4.68B invested in iShares Biotechnology ETF in 2022 Q2 according to their latest regulatory filings, with 75 funds opening new positions, 221 increasing their positions, 334 reducing their positions, and 99 closing their positions.
15% more funds holding in top 10
Funds holding in top 10: 13 → 15 (+2)
0.64% less ownership
Funds ownership: 61.2% → 60.56% (-0.64%)
4% less funds holding
Funds holding: 897 → 858 (-39)
13% less capital invested
Capital invested by funds: $5.4B → $4.68B (-$716M)
24% less first-time investments, than exits
New positions opened: 75 | Existing positions closed: 99
26% less call options, than puts
Call options by funds: $216M | Put options by funds: $294M
34% less repeat investments, than reductions
Existing positions increased: 221 | Existing positions reduced: 334
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$50.1M |
| 2 |
BCM
Bronte Capital Management
Bondi Junction,
Australia
|
+$33.7M |
| 3 |
Jane Street
New York
|
+$24M |
| 4 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$20.4M |
| 5 |
D
Diversified
Wilmington,
Delaware
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$140M |
| 2 |
Bessemer Group
Woodbridge,
New Jersey
|
-$46.8M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$36.1M |
| 4 |
Two Sigma Investments
New York
|
-$35.5M |
| 5 |
JG
Jefferies Group
New York
|
-$29.3M |
IBB Hedge Fund Activity: Q2 2022 in Review
858 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2022, worth a combined $4.68B — down 13% from $5.4B a quarter earlier.
Sellers outnumbered buyers: 99 funds closed out of IBB and 75 opened new positions — a net loss of 24 holders — while 334 trimmed existing stakes and 221 added.
The largest buyer was Royal Bank of Canada, adding an estimated $50.1M. The largest seller was Bank of America, cutting an estimated $140M.
- 858 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2022, down from 897 in Q1 2022.
- Funds reported $4.68B of iShares Biotechnology ETF stock for Q2 2022, down 13% quarter-over-quarter.
- 75 funds opened new iShares Biotechnology ETF positions in Q2 2022 and 99 closed out, a net change of -24 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2022 was Royal Bank of Canada, an estimated $50.1M added.
- The largest iShares Biotechnology ETF seller in Q2 2022 was Bank of America, an estimated $140M sold.
Based on aggregated 13F filings for Q2 2022.